185 related articles for article (PubMed ID: 19862823)
21. Gene regulation in melanoma progression by the AP-2 transcription factor.
Bar-Eli M
Pigment Cell Res; 2001 Apr; 14(2):78-85. PubMed ID: 11310795
[TBL] [Abstract][Full Text] [Related]
22. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
24. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells.
Le E; Zhang H; Blanck G
Anticancer Res; 2005; 25(6B):3889-92. PubMed ID: 16312044
[TBL] [Abstract][Full Text] [Related]
25. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.
Garrido C; Paco L; Romero I; Berruguilla E; Stefansky J; Collado A; Algarra I; Garrido F; Garcia-Lora AM
Carcinogenesis; 2012 Mar; 33(3):687-93. PubMed ID: 22219178
[TBL] [Abstract][Full Text] [Related]
26. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
Radosevich M; Jager M; Ono SJ
Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
[TBL] [Abstract][Full Text] [Related]
28. [Melanoma cell lines as the basis for antitumor vaccine preparation].
Mikhaĭlova IN; Lukashina MI; Baryshnikov AIu; Morozova LF; Burova OS; Palkina TN; Kozlov AM; Golubeva VA; Cheremushkin EA; Doroshenko MB; Demidov LV; Kiselev SL; Larin SS; Georgiev GP
Vestn Ross Akad Med Nauk; 2005; (7):37-40. PubMed ID: 16107020
[TBL] [Abstract][Full Text] [Related]
29. Metastatic melanoma cells evade immune detection by silencing STAT1.
Osborn JL; Greer SF
Int J Mol Sci; 2015 Feb; 16(2):4343-61. PubMed ID: 25690042
[TBL] [Abstract][Full Text] [Related]
30. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
31. Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets.
Sousa JF; Espreafico EM
BMC Cancer; 2008 Jan; 8():19. PubMed ID: 18211678
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional profiles in melanocytes from clinically unaffected skin distinguish the neoplastic growth pattern in patients with melanoma.
Magnoni C; Tenedini E; Ferrari F; Benassi L; Bernardi C; Gualdi G; Bertazzoni G; Roncaglia E; Fantoni L; Manfredini R; Bicciato S; Ferrari S; Giannetti A; Tagliafico E
Br J Dermatol; 2007 Jan; 156(1):62-71. PubMed ID: 17199568
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of metastasis-related genes in human melanoma.
Nyormoi O; Bar-Eli M
Clin Exp Metastasis; 2003; 20(3):251-63. PubMed ID: 12741683
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
35. Identification of metastasis-associated genes by transcriptional profiling of a metastasizing versus a non-metastasizing human melanoma cell line.
Brem R; Hildebrandt T; Jarsch M; Van Muijen GN; Weidle UH
Anticancer Res; 2001; 21(3B):1731-40. PubMed ID: 11497253
[TBL] [Abstract][Full Text] [Related]
36. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
Hussein MR; Elsers DA; Fadel SA; Omar AE
J Clin Pathol; 2006 Mar; 59(3):316-24. PubMed ID: 16505286
[TBL] [Abstract][Full Text] [Related]
37. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
Jaeger J; Koczan D; Thiesen HJ; Ibrahim SM; Gross G; Spang R; Kunz M
Clin Cancer Res; 2007 Feb; 13(3):806-15. PubMed ID: 17289871
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9.
Yin M; Soikkeli J; Jahkola T; Virolainen S; Saksela O; Hölttä E
Am J Pathol; 2014 Mar; 184(3):842-58. PubMed ID: 24412090
[TBL] [Abstract][Full Text] [Related]
39. Identification of genes down-regulated during melanoma progression: a cDNA array study.
Baldi A; Battista T; De Luca A; Santini D; Rossiello L; Baldi F; Natali PG; Lombardi D; Picardo M; Felsani A; Paggi MG
Exp Dermatol; 2003 Apr; 12(2):213-8. PubMed ID: 12702151
[TBL] [Abstract][Full Text] [Related]
40. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma.
Kitago M; Martinez SR; Nakamura T; Sim MS; Hoon DS
Clin Cancer Res; 2009 May; 15(9):2988-94. PubMed ID: 19336521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
